قالب وردپرس درنا توس
Home / Health / University of Kansas Medical Center “Child of Mercy” to offer trial against COVID-19 vaccine

University of Kansas Medical Center “Child of Mercy” to offer trial against COVID-19 vaccine



Health services announced Wednesday that the University of Kansas Medical Center and the Kansas City Children’s Charity are testing a vaccine against COVID-19 in the Kansas area. COVID-19 prevention network The network, known as CoVPN, was established by the National Institutes of Health (NIH) in response to the pandemic. The specific vaccine is AZD1222, originally developed by Oxford University before being purchased by AstraZeneca. “This vaccine is very exciting,” Dr. Mario Castro said at a panel of health systems in Kansas on Monday. Castro is the Deputy Chair of Clinical and Transient Research and a Pulmonologist in the Department of Internal Medicine, University of Kansas. “So much has been thrown at this coronavirus in terms of treatment and prevention, and we finally know that the best strategy against this virus is a vaccine,”

; Castro said. Officials said the vaccine should be launched in mid-late August, the second of three stages of the NIH-funded and AstraZeneca-funded trial. The trial study focuses on efforts at more than 100 sites across the country. Castro and Dr. Barbara Pahud, director of research on childhood infectious diseases in children of mercy and associate professor of pediatrics at the Medical School of KU, will serve as chief investigators in court. “We are working to develop and conduct research to ensure a rapid and thorough evaluation of COVID-19 vaccines,” Pagud said. – Security is our priority №1. I would not offer this vaccine if I was not ready to take it myself. “The study will involve about 30,000 participants nationally – about 1,500 participants from the Kansas Missouri region. The organizers are recruiting adults under the age of 18 who are considered high-risk for contact with COVID-19. Participants will be randomized to identify who receive the vaccine and who receive the placebo.Two of each study participant will receive the vaccine.People who stay at home and severely restrict contact with others will not be eligible.After the trial, placebo participants will be eligible for the vaccine. Castro said the results of a pilot study of the vaccine, recently published in The Lancet, showed promising results for more than 1,000 participants in clinical trials, and that they were mild, including mostly headaches, body aches and fatigue. serious side effects have been reported that Nin hears very much, “Castro said Want to volunteer for the test to get the vaccine, you can register on the CoVPN website, just include a link to the site as KUMC. Or, if you live in the Kansas City area, call Shelby at 913-574-3006. and in Wichita call 316-293-1833.

Health services announced Wednesday that the University of Kansas Medical Center and Kansas City Children’s Charity will bring a test for the COVID-19 vaccine in the Kansas area.

Officials said both hospitals would sue the AstraZeneca vaccine in the region as part of the COVID-19 prevention network. The network, known as CoVPN, was created by the National Institutes of Health (NIH) in response to the pandemic.

The specific vaccine is AZD1222, originally developed by Oxford University before buying AstraZeneca.

“This vaccine is very exciting,” Dr. Mario Castro said at a panel of health systems in Kansas on Monday.

Castro is the Deputy Chair of Clinical and Transient Research and a Pulmonologist in the Department of Internal Medicine, University of Kansas.

“So much has been thrown at this coronavirus in terms of treatment and prevention, and we finally know that the best strategy against this virus is a vaccine,” Castro said.

Officials said the vaccine should be launched in mid-late August, the second of three stages of the NIH-funded and AstraZeneca-funded trial.

The trial study focuses on efforts at more than 100 sites across the country.

Castro and Dr. Barbara Pahud, director of research on childhood infectious diseases in children of mercy and associate professor of pediatrics at the Medical School of KU, will serve as chief investigators in court.

“We are working to develop and conduct research to ensure a rapid and thorough evaluation of COVID-19 vaccines,” Pagud said. – Security is our priority №1. I would not offer this vaccine if I were not ready to take it on my own. ”

The lawsuit will involve about 30,000 participants nationally – about 1,500 from Kansas Missouri.

The organizers recruit adults over the age of 18 who are considered to be at high risk for contact with COVID-19. Participants will be randomized to determine who is receiving the vaccine and who is receiving a placebo. Two out of every three study participants will receive the vaccine. People who stay at home and severely restrict contact with others will not have the right. At the end of the trial, placebo participants will be eligible for the vaccine.

In a news release, Castro said that the results of a pilot study of this vaccine, recently published in The Lancet, showed promising results for more than 1,000 participants in clinical trials. Side effects have been reported to be mild and included headache, body aches and fatigue.

“In fact, more than 1,000 patients have not had any serious side effects, which is very audible,” Castro said.

If you want to volunteer for the vaccine trial, you can register on the CoVPN website, just include a link to the site as KUMC. Or, if you live in the Kansas City area, call Shelby at 913-574-3006. and in Wichita call 316-293-1833.


Source link